Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape.
As RNA-based therapies are gaining more traction in the pharmaceutical industry, with companies looking to expand capabilities to improve the provision of RNA-based treatments in the biotherapeutics field.
Ardena, a leading CDMO specialising in nanomedicines has teamed up with RiboPro, who focus on mRNA and LNP technology, to deliver improvements via a commercial partnership, in the availability of RNA-based therapies to a cGMP level, on a global scale.
The combined skillset of the two companies fulfils an unmet need in the market, with Ardena’s experience in custom development and cGMP manufacturing of lipids and LNP-mRNA formulations combined with the mRNA technologies and expertise in mRNA synthesis and encapsulation from RiboPro. The partnership facilitates a seamless offering in end-to-end production of advanced mRNA and LNP formulations.
This more efficient production process will help drug developers to work more quickly and efficiently, whilst minimising risks associated with scaling production and manufacturing, leader to greater outputs all while being more cost effective.
Harry Christiaens, CEO of Ardena commented:
“The availability of high-quality, stable, and non-immunogenic mRNA in combination with the formulation, process development, analytical development, and manufacturing capabilities of various LNP compositions is critical to achieving the desired payload, encapsulation, stability in circulation, in vivo transfection, and tissue-specific delivery.
“By having all the expertise at the same table, the quality of the new therapeutic and its development plan will be higher from the start, maximising chances of positively impacting the patient.”
“The Ardena/RiboPro alliance will be a science-led and service-strong partnership covering the entire CDMO supply chain from advanced mRNA synthesis to aseptic fill and finishing.
“In a highly competitive niche area of the market the Ardena/RiboPro alliance aspires to differentiate itself from the competition through its fully integrated, highly customer-centric approach. The combination of a state-of-the-art proprietary portfolio of mRNA and LNP technologies with over a decade of nanomedicine development expertise offers our customers an equally unique and beneficial service resulting in accelerated drug development programmes.”
“The strategic alliance with Ardena represents an exciting opportunity for RiboPro,” added Sander van Asbeck, CEO of RiboPro. “Our portfolio of proprietary technologies, and expertise in mRNA synthesis and encapsulation, combined with Ardena’s experience in process development and cGMP manufacturing, will provide our clients with a seamless pathway to advanced mRNA therapeutics with the ultimate goal of getting innovative medicines to patients sooner.
“Our collaboration will also help RiboPro develop a deeper understanding of customer needs and create even more advanced mRNA and LNP solutions accordingly."
Source: Ardena. Ardena and RiboPro Forge Strategic Alliance to Support the RNA Revolution with End-to-End Manufacturing of Advanced mRNA and LNP Solutions. [Date accessed 11/07/2023].
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer.
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shellThe latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin.
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Pharma service provider further expands offerings for clinical development and manufacturing
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
News Pfizer and Thermo Fisher Scientific partner to bring accessible NGS-based testing to international marketsThe collaboration between the pharmaceutical giant and scientific technology provider will aim to bring rapid and localised services to areas around the globe that lack affordable advanced genomic testing for breast and lung cancer.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance